BACKGROUND: Myelofibrosis (MF) includes primary myelofibrosis (PMF) and secondary myelofibrosis (SMF) evolving from essential thrombocythemia (ET) or polycythemia vera (PV). The clinical and molecular heterogeneity of MF remains incompletely characterized in real-world cohorts. METHODS: We retrospectively analyzed 56 patients with MF treated at a single center, including 33 with PMF and 23 with SMF (ET-MF or PV-MF). Clinical characteristics, laboratory parameters, bone marrow pathology, cytogenetic and molecular findings, treatment strategies, and follow-up outcomes were evaluated. RESULTS: mutations displayed higher hemoglobin levels, red blood cell counts, and neutrophil percentages compared with JAK2-wild type patients. Treatment strategies included supportive care, interferon, hydroxyurea, and ruxolitinib. During follow-up, most patients remained alive, although leukemic transformation occurred in a small proportion of PMF cases. CONCLUSIONS: PMF and SMF demonstrate distinct clinical phenotypes despite sharing bone marrow fibrosis as a common endpoint. The mutational landscape highlights the genetic heterogeneity of MF and underscores the importance of integrating clinical, pathological, and molecular information to improve disease characterization and guide individualized management.
Liu et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: